Removal of introns from messenger RNA precursors (pre-mRNA splicing) is an essential
step for the expression of most eukaryotic genes. Alternative splicing enables the regulated …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United
States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small …

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic …

Background: Ibrutinib has revolutionized treatment for several B-cell malignancies.
However, a recent clinical trial where ibrutinib was used in a front-line setting showed …